Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol:

Antonio Avallone,Maria Carmela Piccirillo,Elena Di Gennaro,Carmela Romano,Filomena Calabrese,María Roca,Fabiana Tatangelo,Vincenza Granata,A. Cassata,Ernesta Cavalcanti,Nicola Maurea,Piera Maiolino,Lucrezia Silvestro,Alfonso De Stefano,Francesco Giuliani,Gerardo Rosati,Emiliano Tamburini,Pasquale Aprea,Valeria Vicario,Anna Nappi,Carlo Vitagliano,Rossana Casaretti,Alessandra Leone,Antonella Petrillo,Gerardo Botti,Paolo Delrio,Francesco Izzo,Francesco Perrone,Alfredo Budillon

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol:

2020

Background:Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epige...

Keywords:

anti vegf
in patient
Oxaliplatin
Epigenetics
Oncology
Phases of clinical research
Colorectal cancer
Medicine
Bevacizumab
Valproic Acid
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations